Photo taken from Kamal S. Saini/LinkedIn
May 26, 2024, 08:16
Kamal S. Saini: Enrollment is Ongoing for Phase 3 study CAMBRIA-1
Kamal S. Saini, Executive Medical Director and Head of European Medical Oncology Team at Fortrea Inc., made the following post on LinkedIn
“Approximately 4300 pts will be randomized into the early breast cancer Phase 3 study CAMBRIA-1; enrollment is ongoing!
A phase 3 randomized open-label study of extended adjuvant therapy with camizestrant vs standard endocrine therapy in patients with ER+/HER2– early breast cancer and an intermediate or high risk of recurrence (CAMBRIA 1)
Erika Hamilton; Sibylle Loibl; Naoki Niikura; Priya Rastogi; Kamal S. Saini; Ioanna Gioni; Teresa Klinowska; Ingrid A. Mayer; Mary Stuart; Emilia Syta; Andrew Walding; Thomas Bachelot.”
Read further.
Source: Kamal S. Saini/LinkedIn
.
4300 pts
Andrew Walding
CAMBRIA-1
camizestrant
cancer
early breast cancer
Emilia Syta
enrollment ongoing
ER+/HER2–
Erika Hamilton
Executive Medical Director
extended adjuvant therapy
Fortrea Inc.
Head of European Medical Oncology Team
high risk of recurrence
Ingrid A. Mayer
intermediate risk
Ioanna Gioni
Kamal S. Saini
Mary Stuart
Naoki Niikura
OncoDaily
Oncology
Phase 3 study
Priya Rastogi
randomized open-label study
Sibylle Loibl
standard endocrine therapy
Teresa Klinowska
Thomas Bachelot
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 14, 2024, 00:19
Nov 14, 2024, 00:02
Nov 13, 2024, 23:57
Nov 13, 2024, 23:54
Nov 13, 2024, 23:48
Nov 13, 2024, 23:46